Last reviewed · How we verify
NCT04630444
Riluzole Effects on Hippocampus Biomarkers
EARLY_PHASE1 trial testing Riluzole in Posttraumatic Stress Disorder in 20 participants. Completed in 16 March 2019.
16 March 2019
Quick facts
| Lead sponsor | Mclean Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 16 March 2017 |
| Primary completion | 16 March 2019 |
| Estimated completion | 16 March 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Riluzole (RILUZOLE) — full drug profile →
Conditions studied
- Posttraumatic Stress Disorder — all drugs for Posttraumatic Stress Disorder →
Sponsor
Mclean Hospital
Who can join
Adults 18 to 65, any sex, with Posttraumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.
Singewald N, Sartori SB, Reif A, Holmes A. · · 2023 · cited 40× · PMID 36623804 · DOI 10.1016/j.neuropharm.2023.109418
Verify or expand the search:
- PubMed search for NCT04630444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Riluzole
Trials testing the same drug.
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07414212 — Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosi · Phase 1, PHASE2 · recruiting
- NCT06270108 — The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia · EARLY_PHASE1 · unknown
- NCT06676423 — Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS · Phase 1 · completed
- NCT03660917 — Riluzole in Patients With Spinocerebellar Ataxia Type 7 · Phase 2, PHASE3 · recruiting
Other recruiting trials for Posttraumatic Stress Disorder
Currently open trials in the same condition.
- NCT04529031 — Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry · NA · recruiting
- NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
- NCT07176273 — Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD) · NA · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT06608277 — Ketamine, SGB and Combination Treatment for TBI · Phase 2 · recruiting
Other Mclean Hospital trials
Trials by the same sponsor.
- NCT07519759 — Recovery Inspired Support Engagement (RISE) Pilot · NA · not yet recruiting
- NCT07503093 — Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis · NA · not yet recruiting
- NCT07503067 — Identifying Substance Use Consequences · recruiting
- NCT06816329 — Stress Dynamics and Familial Risk for Depression in Female Adolescents · NA · recruiting
- NCT06876129 — Pharmacologic Augmentation of TMS for Depression With D-serine · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04630444 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mclean Hospital
- Last refreshed: 16 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing